Abrdn Life Sciences Investors
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Abrdn Life Sciences Investors's yearly results (2022–2025), compared with Financial Services companies in United States. Tap ? on any ratio for what it means.
Cash quality
Profit Cash Ratio
—Not applicable for banks
Deposits and loans are a bank's raw material, so cash-flow and debt figures mean something different for banks.
Self-Funding Ratio
—Not applicable for banks
Deposits and loans are a bank's raw material, so cash-flow and debt figures mean something different for banks.
Cash Locked Ratio
—Not applicable for banks
Deposits and loans are a bank's raw material, so cash-flow and debt figures mean something different for banks.
Growth quality
Steadiness Ratio
2/3 · 3/3Sales grew in 2 of the last 3 years; profit grew in 3 of 3.
Steadier than 79% of Financial Services companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
—Not applicable for banks
Deposits and loans are a bank's raw material, so cash-flow and debt figures mean something different for banks.
Cash Cushion Ratio
—Not applicable for banks
Deposits and loans are a bank's raw material, so cash-flow and debt figures mean something different for banks.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (11)
Abrdn Life Sciences Investors owes $0.00 for every $1 it owns. Net profit rose 0% in the year to Sep 2025.
Compared with Financial Services companies in United States · latest annual results Sep 2025.
P/E ratio
2.7Investors pay $2.7 for every $1 of Abrdn Life Sciences Investors' yearly profit, lower than 98% of Financial Services companies in United States.
P/B ratio
0.97The share price is 0.97 times Abrdn Life Sciences Investors' book value per share, lower than 73% of Financial Services companies in United States.
Market cap
$546 MThe total market value of all of Abrdn Life Sciences Investors' shares at today's price (share price × number of shares), smaller than 56% of Financial Services companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$561 MWhat Abrdn Life Sciences Investors would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
$18.44Net worth divided by the number of shares. The share price of $17.95 is 1.0 times this, which is the P/B above.
Return on equity (ROE)
41.4%Abrdn Life Sciences Investors earned 41.4% on its shareholders' money over the last year, higher than 96% of Financial Services companies in United States.
Owes vs Owns
0.00×Abrdn Life Sciences Investors owes $0.00 for every $1 it owns (low), lower than 96% of Financial Services companies in United States. Banks and lenders usually show higher figures.
Dividend yield
12.50%Abrdn Life Sciences Investors pays 12.50% of its share price as dividends a year, higher than 93% of dividend-paying Financial Services companies in United States.
Revenue growth
-0%Revenue fell 0% in the year to Sep 2025.
Profit growth
+0%Net profit rose 0% in the year to Sep 2025.
Profit margin
99.1%Abrdn Life Sciences Investors keeps $99 of every $100 of revenue as net profit.
Questions
What is Abrdn Life Sciences Investors' P/E ratio?
Investors pay $2.7 for every $1 of Abrdn Life Sciences Investors' yearly profit, lower than 98% of Financial Services companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Abrdn Life Sciences Investors: $546 M ÷ $561 M (31 Mar 2026) = 1.0.
What is Abrdn Life Sciences Investors' return on equity?
Abrdn Life Sciences Investors earned 41.4% on its shareholders' money over the last year, higher than 96% of Financial Services companies in United States.
How much does Abrdn Life Sciences Investors owe compared with what it owns?
Abrdn Life Sciences Investors owes $0.00 for every $1 it owns (low), lower than 96% of Financial Services companies in United States. Banks and lenders usually show higher figures.
Does Abrdn Life Sciences Investors pay a dividend?
Yes. Abrdn Life Sciences Investors pays 12.50% of its share price as dividends a year, higher than 93% of dividend-paying Financial Services companies in United States.
Is Abrdn Life Sciences Investors' revenue growing?
Revenue fell 0% in the year to Sep 2025.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.